European regulators have rejected Celgene’s request for an expanded approval of its multiple myeloma drug Revlimid to treat newly diagnosed patients, a stunning setback that slams the brakes on the company's growth.
Whether or not policymakers assist Spain’s struggling economy will make a big difference on how stocks perform next week.
The "Mad Money" host shares his earnings expectations for Biogen Idec, Cummins, Emerson Electric and Chesapeake Energy.
Here’s what “Mad Money” host Jim Cramer expects of select earnings in the days to come.
Since the S&P 500 touched a multi-year high on April 2, the index is down about 3.8 percent. Should investors use the selloff as a buying opportunity?
The Spectrum Pharmaceuticals growth party is over.
Take a look at some of Wednesday’s morning movers:
Technology stocks have been gaining momentum in 2012, up eight of the last nine weeks. However, over the last 12 months, consumer discretionary and health care companies have really powered the rally.
Could there be a correlation between leap years and market performance?
Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.
Although selecting the best of breed in the dog show may be a mysterious science to some, picking outliers in the stock market is vastly more straightforward.
Cramer thinks big pharma stocks could soon pop, so here's his preferred plays.
Find out why he’s bullish on this biotech name.
Mad Money's Cramer, takes a look at Biogen Idec's medical breakthrough drugs and its near-term catalysts for growth this year.
Take a look at some of Monday morning's early movers:
With some leading stocks advancing 50% or more over a period of only 1 year, investors are starting to wonder how much upside can possibly be left.
Cramer makes the call on viewers' favorite stocks.
A partnership with one of the world’s largest biotech companies means a strong year ahead for Isis Pharmaceuticals, CEO Stanley Crooke said Wednesday on “Fast Money.”
The No. 5 performer in the top S&P stocks of 2011 could see more growth ahead, one “Fast Money” pro said.
Sharing perspective on the best trades in 2011; including Visa and Mastercard, with Greg Smith, Sterne Agee analyst.